Abstract:Background: Sarcopenia, characterized by low muscle mass, associates with mortality in patients with cirrhosis. Skeletal muscle area in a single computed tomography image at the level of the third lumbar vertebrate (L3) is a valid representative of whole body muscle mass. Controversy remains regarding applicability of psoas muscle to identify patients at greater risk of mortality. We aimed to determine psoas muscle index (PMI) association with skeletal muscle index (SMI) and to evaluate the capacity of PMI to predict liver transplant waitlist mortality. Methods: We evaluated listed adult patients with cirrhosis from 2012 to 2013 at four North American liver transplant centres. From L3 computed tomography images within 3 months of listing, we determined SMI and PMI expressed by cm2 /m2 . Low SMI was defined as SMI <39 cm2 /m2 in women and <50 cm2 /m2 in men as published by us earlier. Cut-offs for PMI to predict mortality were established using a receiver-operating characteristic analysis. Mortality predictors were determined using competing-risk analysis with reported results as subdistribution hazard ratios (sHRs). Results: Of 353 waitlist candidates, 68% were men, mean age 56 ± 9 years, and Model for End-stage Liver Disease of 16 ± 8 points. Low SMI was present more frequently in men than women (51 vs. 36%, P = 0.02). Moderately strong correlation between SMI and PMI was observed (r > 0.7, P < 0.001). Low PMI (males < 5.1 cm2 /m2 ; females < 4.3 cm2 /m2 ) yielded poor and moderate concordance with low SMI in men and women, respectively (Kappa coefficient 0.31 and 0.63). SMI (39 ± 9 vs. 43 ± 7 cm2 /m2 ; P = 0.009) and PMI (4.4 ± 1.3 vs. 5.2 ± 1.1 cm2 /m2 ; P = 0.001) were lower in women who died and/or were delisted (compared with non-deceased patients) whereas men who died and/or were delisted had only lower SMI (47 ± 7 vs. 51 ± 9 cm2 /m2 ; P = 0.003), but not PMI compared with non-deceased patients. In women, both SMI (sHR 0.94, P = 0.048) and PMI (sHR 0.58, P = 0.002) were predictors of mortality, while in men, SMI was significant (sHR 0.95, P = 0.001) and PMI showed a trend to be (sHR 0.85, P = 0.09) associated with mortality. Overall, 104 patients (29%) were misclassified between SMI and PMI categories. Using PMI cut-offs, 66% and 28% of low SMI men and women, who have a higher risk of mortality, were incorrectly classified as low risk. Conclusions: Skeletal muscle index is a more complete and robust measurement than PMI, especially in men with cirrhosis. Low PMI identifies an incomplete subset of patients at increased risk of mortality indicated by low SMI. Given the poor performance of PMI, SMI should not be substituted by PMI.

Skeletal muscle mass index as a predictor of long-term cirrhosis onset in young non-cirrhotic males with acute-on-chronic liver failure

Muscle mass dynamics is independently associated with long-term liver-related mortality in patients with cirrhosis

Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis

Skeletal muscle mass indexes and nonalcoholic fatty liver disease in Chinese elders

Psoas Muscle Index Can Be Used to Predict Long-Term Mortality in Young Male Patients With Acute-on-Chronic Liver Failure

Establishment of a prognostic model for hospitalized cirrhotic patients with infection based on lumbar muscle mass

Sarcopenia is Associated with Short- and Long-Term Mortality in Patients with Acute-on-chronic Liver Failure

IDDF2020-ABS-0159 A New Diagnostic Index of Skeletal Muscle Mass for Predicting Short-Term Postoperative Complications in Crohn’s Disease

Diagnosis of Sarcopenia Using the L3 Skeletal Muscle Index Estimated From the L1 Skeletal Muscle Index on MR Images in Patients With Cirrhosis

Association of myosteatosis with short-term outcomes in patients with acute-on-chronic liver failure

The relationship between imaging-based body composition abnormalities and long-term mortality in patients with liver cirrhosis

Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis

MRI paraspinous skeletal muscle enhancement: A potential imaging biomarker for assessing clinical liver cirrhosis severity

Evaluation of prognostic scoring systems in liver cirrhosis patients with bloodstream infection.

Muscle Function is Superior to Muscle Mass in Predicting 90-Day Mortality in Patients with Acute-on-chronic Liver Failure: A Prospective Study

CT-based Skeletal Muscle Loss for Predicting Poor Survival in Patients with Hepatocellular Carcinoma Experiencing Curative Hepatectomy Plus Adjuvant Transarterial Chemoembolization: a Preliminary Retrospective Study

Risk of Subsequent Gastrointestinal Disease Assessed by Skeletal Muscle Strength and Mass in a Prospective Cohort Study

Skeletal Muscle Index as a Prognostic Marker for Kidney Transplantation in Older Patients

Diagnostic value of linear skeletal muscle index on CT images for sarcopenia in patients with liver cirrhosis

A self-reported Frailty Index predicts long-term mortality in hospitalized patients with cirrhosis